Question Bank › Recently unlocked door

Recently unlocked door

Recently unlocked door: a fresh permission, approval, or qualification is already producing first real business

Calls Tested
499
Answered YES
24
Hit Rate
4.8%
rare by design

Inogen, Inc. (INGN) — this company's answers

NO on the Q1 2023 call 2023-05-05 F
The model's full reasoning — Q1 2023 call → NO我们需要根据提供的收益电话会议记录来判断是否满足问题中的所有三个条件。问题询问管理层是否描述了公司最近获得了一项权限、批准、资格、认证、上市或准入权，并且通过该新开放门户的第一笔实际业务已经开始，且大部分尚未完成。 条件1：准入是真实且最近获得的（在最近几个季度内授予、完成或生效），形式可以是监管批准、客户或平台资格、认证、许可、处方集或项目列表、供应商名录等。 条件2：第一笔业务已经流动——实际初始订单、客户、发货、注册、安置或收入归因于新准入，无论多小，现在正在发生。 条件3：管理层传达出该准入开放的范围相对于已流动的部分是巨大的——现在可达的人口、市场或活动大部分尚未服务，因此报告的结果只反映了通过门户的第一股涓涓细流。 现在，浏览记录： - 管理层提到：“此外，我们最近收到了关于Rove 6在法国覆盖的确认，并正在等待结果在未来几周内在官方公报上发布。”这涉及Rove 6在法国的覆盖，但似乎仍在等待正式发布，因此可能仍是待定。然而，他们提到“在2023年第一季度，我们在德国获得了Rove 6的报销”以及“我们在法国最近收到了确认” —— 德国报销是最近获得的，法国可能也是。但问题问的是公司最近获得的准入，并且第一笔业务已经开始。对于德国，他们提到“在2023年第一季度，我们在德国获得了Rove 6的报销”——这是准入。但有没有提到第一笔业务已经开始？记录中关于国际B2B：“在推出Rove 6在欧洲……”和“我们在欧洲推出Rove 6之后在2022年底取得了坚实的进展，并在2023年第一季度在德国获得了报销。”没有明确说明通过德国准入已经产生了销售。实际上，他们提到国际B2B销售额下降。所以第一笔业务可能尚未开始。 另一个准入是“我们最近获得了两家大型私人医疗保健支付方的覆盖。”这是关于保险覆盖的准入。他们是否提到第一笔业务？他们提到“我们现在可以覆盖约1.6亿私人保险人口的COPD患者人群。”没有说已经有患者通过此计划。所以这似乎是准入，但第一笔业务可能尚未开始。 还有FDA对Rove 4的批准：“在2022年12月，Inogen收到FDA对Rove 4的批准，我们预计在2023年下半年前在美国推出。”这是准入，但推出尚未开始，因此第一笔业务尚未发生。 “我们的预付款芯片购买”不是准入。 还有“我们在2023年第一季度获得了德国报销” — 但也没有提到销售。 管理层说：“向我们的租赁渠道发展，我们一直在确保更多美国私人支付方的覆盖。在核心CMS覆盖之外，我们最近增加了两家大型私人医疗保健支付方。”他们谈论的是覆盖，但关于“第一笔业务已经开始”没有提及。他们提到“租赁收入增长了25.4%”，但这是来自整体租赁渠道，不一定归因于新的支付方。 关键点是：记录中是否有任何准入是在最近获得的，第一笔业务已经开始，且大部分尚未完成？德国报销可能是最近获得的，但记录没有说通过该准入已经产生销售。实际上，他们可能已经有销售，但记录没有说。根据指示，我们必须使用提供的记录。管理层没有明确说业务已经开始。 因此，条件2未被满足。 条件3：即使有准入，管理层也没有说大部分尚未完成。他们显然将其视为增长机会，但“大部分尚未完成”未明确说明。 因此，我认为陈述不符合要求。答案应为NO。 双重检查：记录中是否有任何准入同时满足所有三个条件？可能“租赁渠道”提到“两家大型私人支付方”——但第一笔业务未提及。“Rove 6在德国” — 未提及第一笔业务。所以答案为NO。

← Back to the full INGN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the company RECENTLY OBTAINED A PERMISSION, APPROVAL, QUALIFICATION, CERTIFICATION, LISTING, OR ACCESS RIGHT it did not previously hold — something granted by an outside authority, customer, partner, or institution that newly allows the company to sell, serve, or operate where it previously could not — AND that real first business through that newly opened door has ALREADY BEGUN, with most of what the access permits still ahead? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent development with all three present: (1) the access is REAL AND RECENTLY IN HAND — granted, completed, or effective within roughly the last few quarters, not pending, applied-for, or expected; the form may be a regulatory approval or clearance, a customer or platform qualification, a certification or accreditation, a license, a formulary or program listing, entry onto an approved-supplier roster, or any equivalent gate that previously excluded the company; (2) FIRST BUSINESS IS ALREADY FLOWING — actual initial orders, customers, shipments, enrollments, placements, or revenue attributable to the new access, occurring now, however small; and (3) management conveys that what the access opens is LARGE RELATIVE TO WHAT HAS FLOWED SO FAR — the population, market, or activity now reachable is mostly unserved, so the reported results reflect only the first trickle through the door. Answer NO if the access is still pending, hoped for, or contingent. NO if the gate was cleared but nothing has yet transacted through it. NO if the access is routine renewal of permissions the company has long held. NO if the business through the new access is already mature and substantially reflected in results. NO if the door and its significance appear only in an analyst's question that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
DXCM DexCom, Inc. Q4 2023 2024-02-08 B+
RDCM RADCOM Ltd. Q4 2023 2024-01-31 A
PFE Pfizer Inc. Q4 2023 2024-01-30 F
NVAX Novavax, Inc. Q3 2023 2023-11-09 F
RVLV Revolve Group, Inc. Q3 2023 2023-11-01 C
APPS Digital Turbine, Inc. Q1 2024 2023-08-08 D
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
HBB Hamilton Beach Brands Holding Company Q3 2022 2022-11-05 C
CMLS Cumulus Media Inc. Q3 2022 2022-10-28 D
YMM Full Truck Alliance Co. Ltd. Q2 2022 2022-08-25 C+
CDXC ChromaDex Corporation Q4 2021 2022-03-09 C+
VNDA Vanda Pharmaceuticals Inc. Q4 2021 2022-02-23 F
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
AMGN Amgen Inc. Q3 2018 2018-10-30 B+
MAS Masco Corporation Q3 2018 2018-10-30 C
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
ATI Allegheny Technologies Incorporated Q1 2018 2018-04-24 B
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
BIIB Biogen Inc. Q2 2017 2017-07-25 B
CNS Cohen & Steers, Inc. Q2 2017 2017-07-20 B
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
PDCO Patterson Companies, Inc. Q3 2017 2017-02-23 C
BMY Bristol-Myers Squibb Company Q4 2016 2017-01-26 F
MAT Mattel, Inc. Q3 2016 2016-10-19 C

How the model reasoned

NVAX · Q3 2023 → YESThe question is: Does management describe that the company RECENTLY OBTAINED A PERMISSION, APPROVAL, QUALIFICATION, CERTIFICATION, LISTING, OR ACCESS RIGHT it did not previously hold — something grant...NO The transcript describes shipments of the updated COVID vaccine that began three weeks ago in the US after competitor launches, along with EU approval in October. However, these details do not meet the criteria for a YES answer because the transcript does not explicitly frame this as a newly obtained permission or access right that the company did not previously hold. Instead, it presents the launch as an update to their existing COVID-19 vaccine platform, with references to prior versions and the ability to update for seasonal strains.
MAT · Q3 2016 → YESThe question is about whether management describes that the company recently obtained a permission, approval, etc., that it didn't previously hold, and that real first business through that newly open...YES The transcript shows management describing a recent new partnership with Toys "R" Us for American Girl, granting exclusive store-within-store access that previously excluded the company. Initial shipping began in the first full quarter, with the distribution build still in early stages and most of the market potential ahead.
MAS · Q3 2018 → YESThe question is about whether management describes that the company recently obtained a permission, approval, etc., that it didn't previously hold, and that real first business through that newly open...YES The transcript shows management describing a recent program access at Menards that enables sales of stock cabinetry, with initial performance already underway and ramping toward an $80 million annual run rate in Q4—indicating the door is newly open and most of the potential volume remains ahead.

More from the question bank

Paid to expand: the company's growth spendinTwo-sided intensityNamed catch-up gapNew leadership already changing what the comThe product is disappearing into reorder rhyComing out of the tunnelAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.